Hepatitis

GNI Announces IND Approval in China for Novel Liver Disease Drug F351

Published in Healthcare Mergers, Acquisitions and Ventures Week, December 8th, 2007

GNI Ltd (TOKYO:2160), a leading biopharmaceutical company in Japan and China, is pleased to announce that the State Food and Drug Administration of China has approved its Investigational New Drug application (IND) for the clinical development of one of its lead drug candidates, F351, for the treatment of liver fibrosis/cirrhosis. GNI's China-based affiliate, Shanghai Genomics, is in the process of preparing its Phase I clinical trial.

The principal causes of liver fibrosis/cirrhosis in Japan and China are viral infection by the Hepatitis B virus or Hepatitis C virus. Alcohol abuse and fatty liver may also lead to liver fibrosis. Fibrosis is a complicated disease process...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week

Source: Healthcare Mergers, Acquisitions and Ventures Week (2007-12-08)

More Articles from Healthcare Mergers, Acquisitions and Ventures Week

"it" Girl Public Relations
'it' Girl Public Relations Adds 'O.N.I.' New Organic Food Delivery Service to Its Lifestyle Division
21st Services
In Progressive Move, 21st Services Forms Independent Medical Advisory Board to Study Longevity, Mortality Risk
23andMe, Inc.
23andMe to Hold Webcast Media Briefing
454 Life Sciences
The Max Planck Institute in Leipzig Acquires Second Genome Sequencing FLX(TM) System
50 Million Pound Challenge
Challenge Tops 1,040,000 lbs, National Tour Makes 14th Stop in New Orleans for Bayou Classic
AARP
Divided We Fail 'Faith Week' to Raise Health and Financial Security Issues in Communities of Faith
More from this issue of Healthcare Mergers, Acquisitions and Ventures Week

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry